Ribosomal protein L23a pseudogene 49 (RPL23AP49)

Ribosomal protein L23a pseudogene 49 (RPL23AP49) is a human pseudogene located on chromosome 3 (NCBI Gene ID: 653236), annotated in databases such as Ensembl (ENSG00000243422) and the HUGO Gene Nomenclature Committee (HGNC:35689)[3][4][6]. RPL23AP49 is a member of a large group of pseudogenes derived from the ribosomal protein L23a gene family. As a pseudogene, RPL23AP49 does not encode a functional protein and has no established direct biological or molecular role. Its transcript may potentially contribute to gene regulation via noncoding RNA mechanisms, but this has not been definitively shown. Recent research on similar pseudogenes (e.g., RPL23AP53) indicates that expression levels might be associated with clinical parameters in melanoma, such as patient survival and immune cell infiltration[1]. However, there is no evidence to date that RPL23AP49 is a therapeutic target, encodes a druggable protein, or interacts with any drugs. The biological significance of RPL23AP49 in health and disease remains unclear and requires further study. **Justification of status (\"is_target\" and \"is_incorrect\")**: - **is_target: false** because RPL23AP49 encodes a pseudogene, not a functional protein or RNA with known druggability or molecular targeting potential[3][4][6]. - **is_incorrect: true** because pseudogenes are not conventional therapeutic targets, and there are no established disease associations, functions, or specific pharmacological interactions; use as a \"target\" in a drug-discovery context would be incorrect. **Summary**: RPL23AP49 is a noncoding pseudogene, not a therapeutic target, with no known direct biological function or established clinical utility beyond possible biomarker potential for specific cancer research contexts[1][3][4][6].

Other names

RPL23A_12_383RPL23AP49